1. Scrip

Is The US Less Attractive Than India? A Proxy Comparison Via Strides And Torrent

 
• By Vibha Ravi

Scrip examines Torrent Pharma and Strides Pharma’s divergent strategies and Q4 financial performance in the US and India while presenting an infographic to compare market-wise metrics

Vector of US and India Flags In Human Form
US And India Are Two Major Markets For Indian Pharma Majors • Source: Shutterstock

Torrent Pharmaceuticals Ltd. and Strides Pharma Science Limited’s fourth quarter results for FY23 have presented an opportunity to compare how the former’s strategy to focus on the Indian market has fared against the latter’s emphasis on the US geography.

A key influencer of any company’s performance is the commercial markets it chooses to operate in. While multiple factors like product mix, supply chain components, demand dynamics and cost base...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.